Effect of drospirenone on serum potassium and drospirenone pharmacokinetics in women with normal or impaired renal function

Journal of Clinical Pharmacology

Volumn 46, Issue 8, 2006, Pages 867-875

  Schürmann, Rolf ^a   Blode, Hartmut ^a   Benda, Norbert ^a   Cronin, Maureen ^a   Küfner, Andreas ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Drospirenone; Hyperkalemia; Pharmacokinetics; Progestin; Renal function

Indexed keywords

DROSPIRENONE; POTASSIUM;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DRUG EFFECT; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HYPERKALEMIA; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; OPEN STUDY; POTASSIUM BLOOD LEVEL; RISK FACTOR; STEADY STATE;

ADULT; ALDOSTERONE ANTAGONISTS; ANDROSTENES; CREATININE; FEMALE; HUMANS; HYPERKALEMIA; MIDDLE AGED; MODELS, BIOLOGICAL; POTASSIUM; REFERENCE VALUES; REGRESSION ANALYSIS; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX; SODIUM;

EID: 33745881938     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1177/0091270006289973     Document Type: Article

References (18)

1. Oelkers W, Berger V, Bolik A, et al. Dihydrospirorenone, a new progestogen with antimineralocorticoid activity: effects on ovulation, electrolyte excretion, and the renin-aldosterone system in normal women. J Clin Endocrinol Metab. 1991;73: 837-942.
2. Follow K, Juchem M, Elger W, Jacobi N, Hoffmann G, Mobus V. Dihydrospirorenone (ZK30595): a novel synthetic progestogen-characterization of binding to different receptor proteins. Contraception. 1992;46:561-574.
3. Muhn P, Krattenmacher R, Beier S, Elger W, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Pharmacologic characterization in animal models. Contraception. 1995;51:99-110.
4. Muhn P, Fuhrmann U, Fritzemeier BCH, Krattenmacher R, Schillinger E. Drospirenone: a novel progestogen with antimineralocorticoid and antiandrogenic activity. Ann NY Acad Sci. 1995;761:311-335.
5. Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen. Contraception. 2000;62:29-38.
6. Blode H. Pharmacokinetics of drospirenone. Gynaecology Forum. 2002;7:18-23.
7. Parsey KS, Pong A. An open-lahel, multicenter study to evaluate Yasmin, a low-dose combination oral contraceptive containing drospirenone, a new progestogen. Contraception. 2000;61:105-111.
8. Huber J, Foidart JM, Wuttke W, et al. Efficacy and tolerability of a monophasic oral contraceptive containing ethinylestradiol and drospirenone. Eur J Contracept Reprod Health Care. 2000;5:25-34.
9. Waeber B, Nussberger J, Brunner HR. Clinical applications of antimineralocorticoids. J Steroid Biochem. 1988;31:739-744.
10. Rimmer JM, Horn JF, Gennari FJ. Hyperkalemia as a complication of drug therapy. Arch Intern Med. 1987;147:867-869.
11. Perazella MA. Trimethoprim-induced hyperkalemia: clinical data, mechanism, prevention and management. Drug Saf. 2000;22:227-236.
12. Greenberg A. Hyperkalemia: treatment options. Semin Nephrol. 1998;18:46-57.
13. Oelkers W, Foidart JM, Dombrovicz N, Welter A, Heithecker R. Effects of a new oral contraceptive containing an antimineralocorticoid progestogen, drospirenone, on the renin-aldosterone system, body weight, blood pressure, glucose tolerance, and lipid metabolism. J Clin Endocrinol Metab. 1995;80:1816-1821.
14. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
15. Blode H, Wuttke W, Loock W, Röll G, Heithecker R. A 1-year pharmacokinetic investigation of a novel oral contraceptive containing drospirenone in healthy female volunteers. Eur J Contracept Reprod Health Care. 2001:256-264.
16. Louton T, Kuhnz W, Dibbelt L, Knuppen R. Weighted serum pools in comparison to the trapezoidal rule for estimating AUCs for ethinyl estradiol: the relationship of the variance of the determination to the interindividual variance. Eur J Clin Pharmacol. 1994;46:77-81.
17. Hu OY, Curry SH. Calculation of fraction bound in equilibrium dialysis with special reference to drug losses by decomposition and absorption. Biopharm Drug Dispos. 1986;7:211-214.
18. Preston RA, White WB, Pitt B, Bakris G, Norris PM, Hanes V. Effects of drospirenone/17-β estradiol on blood pressure and potassium balance m hypertensive postmenopausal women. Am J Hypertens. 2005;18:797-804.